The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

Consumers Now Have More Choices to Purchase the Visby Device Featuring 30-Minute, Lab-Quality ResultsSAN JOSE, Calif.--(BUSINESS WIRE)--Today, Visby Medical announced two new relationships that will ...

NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has ...

Labcorp Holdings Inc. LH, or Labcorp, is well-poised to grow in the coming quarters due to its strong, consistent performance in high-growth areas. In recent years, the company has built a significant ...

BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside ...

Labcorp Holdings ( ($LH) ) has issued an update. On December 30, 2025, Labcorp announced it would participate in a fireside chat at the 44th ...

Hologic trades at a forward one-year price-to-sales (P/S) of 3.86X, higher than its median. In contrast, Labcorp’s forward ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...